CHS-1420: Phase III started

Coherus began the double-blind Phase III PsOsim trial to compare CHS-1420 for 23 weeks vs. Humira adalimumab from AbbVie Inc. (NYSE:ABBV, Chicago, Ill.) for 16 weeks in about 500 patients. Patients ...